Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
70.13
+1.58 (+2.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,183,733
Open
69.67
Bid (Size)
70.17 (1)
Ask (Size)
70.20 (1)
Prev. Close
68.55
Today's Range
69.38 - 70.49
52wk Range
60.47 - 76.56
Shares Outstanding
N/A
Dividend Yield
1.33%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
European Stock: AstraZeneca
April 22, 2024
AstraZeneca PLC is a science-led biopharmaceutical company. The company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and...
Via
Talk Markets
Looking At AstraZeneca's Recent Unusual Options Activity
April 19, 2024
Via
Benzinga
Performance
YTD
+2.53%
+2.53%
1 Month
+6.48%
+6.48%
3 Month
+4.45%
+4.45%
6 Month
+11.23%
+11.23%
1 Year
-7.49%
-7.49%
More News
Read More
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
April 19, 2024
Via
Benzinga
Topics
Brexit
Exposures
Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
April 19, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
A Closer Look at AstraZeneca's Options Market Dynamics
April 03, 2024
Via
Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Via
Benzinga
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Via
Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
April 16, 2024
Via
Benzinga
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
April 16, 2024
From
AstraZeneca
Via
Business Wire
3 Pharma Stocks That Are Money-Printing Machines in 2024
April 15, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
April 14, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
Via
Benzinga
Exposures
Product Safety
Biotech Innovations Paving the Way in Breast Cancer Fight
April 11, 2024
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Product Safety
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
April 11, 2024
Via
Benzinga
Exposures
Product Safety
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
April 11, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
Via
Benzinga
Exposures
Product Safety
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
April 07, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
April 05, 2024
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
April 05, 2024
From
AstraZeneca
Via
Business Wire
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial
April 05, 2024
Via
Benzinga
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
April 05, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
April 02, 2024
Via
Benzinga
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
April 02, 2024
From
AstraZeneca
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
April 01, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.